Prospective CT Assessment After DCB (PREVAIL)
PRospective Evaluation of Vascular Alterations in CT Angiography After Intervention With Drug-coated Balloon (PREVAIL) Study
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Junpil Yun, MD
- Phone Number: 82-10-8001-9969
- Email: junpilyun@gmail.com
Study Contact Backup
- Name: Bon-kwon Koo, MD, PhD
- Phone Number: 82-2-2072-2062
- Email: bkkoo@snu.ac.kr
Study Locations
-
-
-
Seoul, South Korea
- Recruiting
- Seoul National University Hospital
-
Contact:
- Junpil Yun, MD
- Phone Number: 82-10-8001-9969
- Email: junpilyun@gmail.com
-
Contact:
- Bon-kwon Koo, MD, PhD
- Phone Number: 82-2-2072-2062
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with Age ≥ 19
- Patients who took CCTA and were found to have coronary artery disease requiring reperfusion
- Patients who underwent DCB within 3 months after CCTA and whose clinical presentation remained largely unchanged from the time of CCTA.
- The target lesion is a de novo lesion with a vessel diameter between 2.25mm and 3.00mm
- Patients deemed suitable for coronary intervention using drug-coated balloon by clinical assessment
- Patients who have been adequately informed about this study and have voluntarily provided written consent to participate.
Exclusion Criteria:
- The target lesion is an in-stent restenosis lesion
- Patient requiring emergency salvage stenting in target lesion
- Patients with a stent previously implanted in the same vessel
- Lesions involving chronic total occlusion or prior coronary artery bypass grafting (CABG).
- Patients with eGFR (estimated glomerular filtration rate) < 45 ml/min/1.73mm2
- Patients with coronary artery calcium score ≥ 1000 as determined by CCTA
- Patients with an expected survival of less than 5 years
- Pregnant or breastfeeding patients
- Patients deemed inappropriate to participate in this study based on the judgment of study investigators
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Patients treated with a drug-coated balloon for de novo lesions.
Patients who underwent DCB within 3 months after CCTA and whose clinical presentation remained largely unchanged from the time of CCTA.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes in ΔFFR CT before and after DCB procedure
Time Frame: From baseline CCTA to follow-up CCTA performed 2 years after the index PCI
|
From baseline CCTA to follow-up CCTA performed 2 years after the index PCI
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes in plaque characteristics before and after DCB procedure
Time Frame: From baseline CCTA to follow-up CCTA performed 2 years after the index PCI
|
From baseline CCTA to follow-up CCTA performed 2 years after the index PCI
|
|
Changes in diameter stenosis before and after DCB procedure
Time Frame: From baseline CCTA to follow-up CCTA performed 2 years after the index PCI
|
From baseline CCTA to follow-up CCTA performed 2 years after the index PCI
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- H-2404-105-1532
- ERP-2024-13777 (Other Grant/Funding Number: Medtronic)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.